- Home
- CVKD vs IBO Comparison
CVKD vs IBO Comparison
Compare CVKD & IBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- IBO
- Stock Information
- Founded
- CVKD 2022
- IBO 2018
- Country
- CVKD United States
- IBO United States
- Employees
- CVKD N/A
- IBO N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- IBO
- Sector
- CVKD Health Care
- IBO
- Exchange
- CVKD Nasdaq
- IBO NYSE
- Market Cap
- CVKD 20.8M
- IBO 17.9M
- IPO Year
- CVKD 2023
- IBO 2024
- Fundamental
- Price
- CVKD $19.72
- IBO $1.95
- Analyst Decision
- CVKD Strong Buy
- IBO
- Analyst Count
- CVKD 1
- IBO 0
- Target Price
- CVKD $32.00
- IBO N/A
- AVG Volume (30 Days)
- CVKD 51.3K
- IBO 19.7K
- Earning Date
- CVKD 03-10-2025
- IBO 02-23-2025
- Dividend Yield
- CVKD N/A
- IBO N/A
- EPS Growth
- CVKD N/A
- IBO N/A
- EPS
- CVKD N/A
- IBO 0.01
- Revenue
- CVKD N/A
- IBO N/A
- Revenue This Year
- CVKD N/A
- IBO N/A
- Revenue Next Year
- CVKD N/A
- IBO N/A
- P/E Ratio
- CVKD N/A
- IBO $126.63
- Revenue Growth
- CVKD N/A
- IBO N/A
- 52 Week Low
- CVKD $5.40
- IBO $1.16
- 52 Week High
- CVKD $21.30
- IBO $3.25
- Technical
- Relative Strength Index (RSI)
- CVKD 59.55
- IBO N/A
- Support Level
- CVKD $19.07
- IBO N/A
- Resistance Level
- CVKD $19.56
- IBO N/A
- Average True Range (ATR)
- CVKD 1.48
- IBO 0.00
- MACD
- CVKD 0.01
- IBO 0.00
- Stochastic Oscillator
- CVKD 69.69
- IBO 0.00
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
About IBO IMPACT BIOMEDICAL INC
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza.